華森製藥(002907.SZ):收到氯普噻噸片、阿昔洛韋片的藥品再註冊批准通知書
格隆匯2月19日丨華森製藥(002907.SZ)公佈,公司於近日收到重慶市藥品監督管理局核准簽發的5份《藥品再註冊批准通知書》。相關藥品分別為氯普噻噸片(12.5mg)、氯普噻噸片(15mg)、氯普噻噸片(25mg)、氯普噻噸片(50mg)、阿昔洛韋片(0.2g)。
氯普噻噸片:用於急性和慢性精神分裂症,適用於伴有精神運動性激越、焦慮、抑鬱症狀的精神障礙。
阿昔洛韋片:(1)單純皰疹病毒感染:用於生殖器皰疹病毒感染初發和復發病例,對反覆發作病例口服本品用作預防;(2)帶狀皰疹:服用於免疫功能正常者帶狀皰疹和免疫缺陷者輕症病例的治療;(3)免疫缺陷者水痘的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.